You are here

Lilly profit hit by Covid-19 drug development costs, weak demand

AK_elil_2710.jpg
Eli Lilly and Co fell short of analysts' expectations for third-quarter profit on Tuesday due to increased costs to develop Covid-19 therapies and lower demand for some its major drugs, including diabetes treatment Trulicity.

[INDIANAPOLIS] Eli Lilly and Co fell short of analysts' expectations for third-quarter profit on Tuesday due to increased costs to develop Covid-19 therapies and lower demand for some its major drugs, including diabetes treatment Trulicity.

Lilly is one of the handful of companies racing...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes